Clenpiq, approved by the Food and Drug Administration (FDA) in November 2017, is a ready-to-drink, low-volume bowel prep; it does not need to be diluted prior to administration. The solution combines sodium picosulfate, a stimulant laxative, and magnesium oxide and anhydrous citric acid, which form magnesium citrate, an osmotic laxative. The stimulant laxative acts directly on the colonic mucosa to stimulate colonic peristalsis whereas the osmotic agent causes water to be retained within the gastrointestinal tract.
Clenpiq should not be used in patients with severe renal impairment (CrCl <30mL/min), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in Clenpiq.
Clenpiq is available as a carton containing 2 bottles, each holding 160mL of cranberry flavored solution. Two doses of Clepiq are required for a complete preparation for colonoscopy. An 8oz cup for measuring fluids for hydration is also included.
For more information call (888) 337-7464 or visit Clenpiq.com.